2025-12-19 - Analysis Report
Okay, here's a comprehensive report on Merck & Co. (MRK) based on the provided data.

**1) Return Rate Comparison & Alpha/Beta Analysis**

*   **Company Overview:** Merck & Co. Inc. is a global pharmaceutical company that develops and manufactures healthcare solutions.
*   **Cumulative Return:** MRK: 19.83%, VOO (S&P 500): 99.09%
*   **Divergence:** MRK is underperforming the S&P 500, with a divergence of -82.8. The relative divergence of 16.8 indicates it is closer to its minimum historical underperformance against the S&P 500 than its maximum outperformance within the observed timeframe.

**Alpha, Beta Analysis Table:**

| Year      | CAGR   | MDD   | Alpha   | Beta  | Cap(B) |
|-----------|--------|-------|---------|-------|--------|
| 2015-2017 | 1.0%   | 68.5% | -28.0%  | 0.0   | 134.1  |
| 2016-2018 | 36.0%  | 69.8% | 21.0%   | -0.0  | 182.1  |
| 2017-2019 | 40.0%  | 69.8% | 18.0%   | 0.3   | 216.8  |
| 2018-2020 | 16.0%  | 79.6% | -8.0%   | 0.3   | 195.0  |
| 2019-2021 | 2.0%   | 79.6% | -44.0%  | 0.7   | 191.4  |
| 2020-2022 | 15.0%  | 79.6% | 16.0%   | 0.7   | 277.1  |
| 2021-2023 | 33.0%  | 79.6% | 31.0%   | 0.3   | 272.3  |
| 2022-2024 | -4.0%  | 79.6% | -25.0%  | 0.2   | 248.5  |
| 2023-2025 | -29.0% | 71.5% | -93.0%  | 1.7   | 251.5  |

*   **Analysis:**
    *   **CAGR:** Fluctuating significantly over the periods.  The last period (2023-2025) shows a substantial negative CAGR, indicating poor performance.
    *   **MDD:**  Maximum Drawdown is high across all periods, suggesting significant potential for loss from peak to trough.
    *   **Alpha:**  Alpha is mostly negative, indicating underperformance compared to the benchmark. The most recent period has a very large negative alpha, contributing to the divergence from the S&P 500.
    *   **Beta:** Beta varies but is generally below 1.0, suggesting the stock is less volatile than the overall market. The latest period (2023-2025) shows a significantly higher beta (1.7), indicating increased sensitivity to market movements and potentially contributing to the recent negative performance.
    *   **Cap:** The market cap fluctuates, indicating changes in the company's overall valuation.

**2) Recent Stock Price Fluctuations**

*   **Current Close:** 100.69
*   **Last Market Data:**
    *   Price: 100.69
    *   Previous Close: 99.18
    *   Change: 1.52
*   **Moving Averages:**
    *   5-day SMA: 99.74
    *   20-day SMA: 100.2535
    *   60-day SMA: 91.4192

*   **Analysis:** The stock price is currently above its 5-day and 20-day SMAs, suggesting a short-term upward trend. The current price is also significantly above the 60-day SMA, indicating a longer-term upward trend, although the very recent performance (as seen in the 5-day SMA) suggests a possible leveling off.

**3) RSI, PPO, Market Risk Indicator, and Expected Return Analysis**

*   **Market Risk Indicator (MRI):** 0.7 (Medium Investment Recommended)
*   **RSI:** 39.11 (Approaching Oversold)
*   **PPO:** -0.603
*   **Hybrid Signal:** cash_0%_Buy 100% of cash
*   **Recent Relative Divergence Change (20 days):** 3.1 (+): 단기상승 (Short-term increase)
*   **Expected Return:** -52.3%

*   **Analysis:**
    *   The Medium MRI suggests the stock is currently a moderately risky investment.
    *   The RSI of 39.11 suggests the stock is approaching oversold territory, potentially indicating a buying opportunity.
    *   The negative PPO suggests a bearish (downward) trend.
    *   The hybrid signal is bullish.
    *   The recent increase in relative divergence hints at a short-term upward trend relative to the S&P 500.
    *   The *very* negative Expected Return is a major red flag, suggesting significant underperformance compared to the S&P 500 over the long term if the current conditions persist.

**4) Recent News & Significant Events**

*   **Positive:**
    *   Analyst Upgrade & Price Target Increase (MarketBeat, GuruFocus): BMO Capital upgraded MRK and raised the price target to $130. This indicates positive sentiment from at least one analyst firm.
    *   FDA Fast-Track Vouchers & Keytruda-Padcev Trial Win (ts2.tech): Positive clinical trial results and FDA fast-track designation are generally good news for pharmaceutical companies.
    *   Stock Trading Up (Yahoo Finance): An earlier article mentioned MRK stock was trading up.
    *   Why Is Merck Stock Surging? (Forbes)

*   **Negative/Mixed:**
    *   Stock Down 3% (Quiver Quantitative):  Contradicts some of the positive news, indicating recent price weakness.

*   **Analysis:** The news is mixed, with positive catalysts like analyst upgrades and clinical trial successes offset by reports of recent price declines. The analyst upgrades and positive clinical news are encouraging, but the recent price decline and the data from Quiver Quantitative should be taken into account.

**4-2) Analyst Opinions**

*   **Consensus:** Buy (1.97)
*   **Target Price:** Average: $110.04, High: $139.00, Low: $83.00

*   **Analysis:** The analyst consensus is generally positive, with a "Buy" rating and an average price target above the current price. This suggests that analysts, on average, expect the stock price to increase. However, the wide range between the high and low target prices indicates uncertainty about the stock's future performance.

**5) Recent Earnings Analysis**

| Date       | EPS  | Revenue   |
|------------|------|-----------|
| 2025-11-05 | 2.32 | 17.28 B$  |
| 2025-08-05 | 1.76 | 15.81 B$  |
| 2025-05-02 | 2.01 | 15.53 B$  |
| 2024-11-06 | 1.25 | 16.66 B$  |
| 2025-11-05 | 1.25 | 16.66 B$  |

*   **Analysis:** Earnings per share (EPS) and revenue have generally increased over the past year. The most recent EPS of 2.32 and revenue of 17.28 B$ represent the highest values in the provided data.  However, the duplicated 2025-11-05 | 1.25 | 16.66 B$ entry is concerning.  This could indicate data entry error or restatement.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue    | Profit Margin |
|------------|------------|---------------|
| 2025-09-30 | $17.28B    | 77.69%        |
| 2025-06-30 | $15.81B    | 77.50%        |
| 2025-03-31 | $15.53B    | 77.98%        |
| 2024-12-31 | $15.62B    | 75.50%        |
| 2024-09-30 | $16.66B    | 75.51%        |

**Capital and Profitability:**

| Quarter    | Equity     | ROE     |
|------------|------------|---------|
| 2025-09-30 | $51.85B    | 11.16%  |
| 2025-06-30 | $48.99B    | 9.04%   |
| 2025-03-31 | $48.34B    | 10.51%  |
| 2024-12-31 | $46.31B    | 8.08%   |
| 2024-09-30 | $44.50B    | 7.09%   |

*   **Analysis:**
    *   **Revenue and Profit Margin:** Revenue has generally increased. The profit margin is extremely high and relatively stable, indicating strong operational efficiency.
    *   **Equity and ROE:** Equity has steadily increased, suggesting growth in the company's net assets. Return on Equity (ROE) has also increased, indicating improved profitability relative to shareholder equity.

**7) Comprehensive Analysis (Summary)**

*   **Performance:** MRK has significantly underperformed the S&P 500 over the period reviewed. This is reflected in the large negative divergence and the negative Alpha values.
*   **Risk:** While the Beta is generally below 1, the MDD figures show a high potential for losses. The recent increase in Beta to 1.7 is concerning.
*   **Recent Trends:** There are mixed signals. The recent stock price has shown a short-term upward trend.
*   **Financial Health:**  The company has strong revenue and profitability, as reflected in high profit margins and rising ROE.
*   **Analyst Sentiment:**  Analysts are generally positive, with a "Buy" consensus and price targets above the current price. However, the negative expected return in contrast to the hybrid signal remains concerning.
*   **News & Events:** The news is mixed, with positive catalysts like analyst upgrades and clinical trial successes offset by reports of recent price declines.

**Conclusion:**

The data presents a mixed picture for MRK. The company appears financially healthy with good revenue and profit margins, and analysts have a generally positive outlook. However, the stock has significantly underperformed the S&P 500, and the negative expected return is a major concern. The recent increase in Beta suggests increased volatility. The duplicated 2025-11-05 is concerning and requires further investigation.

**Recommendation:**

Given the underperformance, high MDD, increased Beta, and negative expected return, **caution is advised**. The positive analyst sentiment and solid financial performance are encouraging, but the negative indicators cannot be ignored. A potential investor should carefully consider their risk tolerance and conduct further due diligence before investing in MRK. The duplicated earnings data should also be verified for accuracy.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.